Vanguard Group Inc. Acquires 49,802 Shares of Kiniksa Pharmaceuticals International, plc $KNSA

Vanguard Group Inc. boosted its holdings in Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 1.6% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,112,937 shares of the company’s stock after buying an additional 49,802 shares during the period. Vanguard Group Inc.’s holdings in Kiniksa Pharmaceuticals International were worth $128,409,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. EverSource Wealth Advisors LLC boosted its holdings in shares of Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after acquiring an additional 532 shares during the period. Osaic Holdings Inc. purchased a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter worth about $31,000. Quantbot Technologies LP purchased a new stake in Kiniksa Pharmaceuticals International during the 2nd quarter worth about $43,000. Quarry LP bought a new position in Kiniksa Pharmaceuticals International in the 3rd quarter worth about $44,000. Finally, TD Waterhouse Canada Inc. boosted its stake in Kiniksa Pharmaceuticals International by 1,673.9% in the 3rd quarter. TD Waterhouse Canada Inc. now owns 2,040 shares of the company’s stock worth $79,000 after purchasing an additional 1,925 shares during the period. Institutional investors own 53.95% of the company’s stock.

Insider Activity at Kiniksa Pharmaceuticals International

In related news, CAO Michael R. Megna sold 6,625 shares of the business’s stock in a transaction that occurred on Thursday, April 9th. The stock was sold at an average price of $46.69, for a total value of $309,321.25. Following the completion of the sale, the chief accounting officer owned 27,418 shares in the company, valued at $1,280,146.42. The trade was a 19.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 58,424 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $53.71, for a total value of $3,137,953.04. Following the completion of the sale, the insider directly owned 65,623 shares of the company’s stock, valued at approximately $3,524,611.33. This represents a 47.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 655,991 shares of company stock worth $34,167,123 in the last quarter. 53.48% of the stock is owned by company insiders.

Kiniksa Pharmaceuticals International Stock Performance

Shares of NASDAQ:KNSA opened at $58.37 on Tuesday. Kiniksa Pharmaceuticals International, plc has a 52-week low of $24.85 and a 52-week high of $59.75. The firm has a fifty day moving average of $47.67 and a 200 day moving average of $43.86. The firm has a market capitalization of $4.49 billion, a PE ratio of 64.86 and a beta of 0.17.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.27 earnings per share for the quarter, beating analysts’ consensus estimates of $0.18 by $0.09. Kiniksa Pharmaceuticals International had a return on equity of 13.26% and a net margin of 9.69%.The business had revenue of $214.27 million for the quarter, compared to the consensus estimate of $206.11 million. During the same quarter last year, the business posted $0.11 earnings per share. The company’s revenue for the quarter was up 55.5% on a year-over-year basis. On average, sell-side analysts forecast that Kiniksa Pharmaceuticals International, plc will post 1.24 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on KNSA. Wall Street Zen upgraded Kiniksa Pharmaceuticals International from a “hold” rating to a “strong-buy” rating in a research report on Monday, May 4th. Weiss Ratings raised shares of Kiniksa Pharmaceuticals International from a “hold (c)” rating to a “hold (c+)” rating in a research note on Wednesday, May 6th. Wedbush upped their target price on shares of Kiniksa Pharmaceuticals International from $58.00 to $59.00 and gave the stock an “outperform” rating in a report on Wednesday, April 29th. Jefferies Financial Group raised their price target on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a report on Tuesday, April 28th. Finally, Wells Fargo & Company boosted their price target on shares of Kiniksa Pharmaceuticals International from $53.00 to $57.00 and gave the company an “overweight” rating in a research report on Wednesday, April 29th. Seven analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $60.86.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.